Add human relevance to your drug development
Our preclinical platform enables the ex vivo testing of anticancer agents on human tumors with their native tumor microenvironment (TME) preserved. We help biotech and pharmaceutical companies make better decisions by leveraging our patient-derived tumor model before they enter the clinic.
MISO Chip's microfluidic platform circumvents the usual limitations of primary tissue assays.
Human relevance
Undissociated, uniform tumor fragments (ø400µm) capture the heterogeneity of the primary tissue
Throughput
5 to 10x greater than standard explant models
Viability
World record of 15 days ex vivo without perfusion, that’s 5x longer than other explant platform
Services
Through a fee for service business model, we design custom studies for our clients to test their lead compounds with our tumor-on-a-chip technology.
Target Engagement and Pathway Modulation Studies
Drug Combination Testing
Efficacy Assays
Dosing Regimen Assessment
Products for Academia
Ex vivo Chips
MISO Chip offers its microfluidic devices to academic researchers in translational oncology. Whether its for following molecular pathways or developing predictive assays, our lab-on-chips provide a simple solution for 3D cell culture of micro-dissected tissues (MDT). No specialized equipment, no expensive reagents needed, our devices are handled with a standard pipette and enable users to quickly do their own ex vivo experiments.
In vitro Chips
MISO Chip also developed spheroid devices that can be used to cost-effectively grow large number of spheroids from your favorite cell line.
Contact us for product information.
